web-ADC Pharma Newsweb-ADC.com delivers up-to-the-minute pharmaceutical news and information.Belly Fat Linked to Stroke Risk- August 15, 2008 (WebMD) We know what being overweight and obese can contribute to heart disease and heart attacks but does having extra weight around your belly increase your risk of strokehttp://www.webmd.com/stroke/news/20080814/belly-fat-a-risk-factor-for-stroke Algeta Reports Results for the Second Quarter and First Half Year 2008- August 15, 2008 (PharmaLive) Oslo, Norway, 13 August 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announces its results for the second quarter 2008. A presentation to analysts, investors and the press will take place today in Oslo at 08:15 CET and a conference call will take place at 14:30 CET details below.http://www.pharmalive.com/News/index.cfm?articleid=563696&categoryid=36%2C61 University Hospitals Receives $22.6 Million Donation from Harrington and McLaughlin Families- August 14, 2008 (Yahoo) CLEVELAND, Aug. 14 PRNewswire -- University Hospitals has received one of the largest financial gifts in its 143-year history -- a $22.6 million donation from well-known Northeast Ohio philanthropists, the Harrington and McLaughlin families. The donation, believed to be among the largest in the country given to a cardiovascular institute, is unique in that it is earmarked for the development of innovative technologies and clinical advancements for the early diagnosis and prevention of...http://biz.yahoo.com/prnews/080814/clth100.html?.v=73 224,000 Californians Sign Petition Urging the Governor and Legislature to Rescind Medi-Cal Cuts- August 14, 2008 (VPO) SACRAMENTO, Calif. --(Business Wire)-- Aug. 14, 2008 The ten percent Medi-Cal provider cuts that went into effect on July 1, 2008 have already created hardships throughout California for pharmacists and the patients they serve. More and more pharmacies have been forced to stop filling Medi-Cal prescriptions because pharmacies lose money on nearly every prescription filled. To date, 224,281 Californians have signed petitions urging the Governor and Legislature to rescind the cuts to ensure.http://www.virtualpressoffice.com/press/index.jsp?pressId=1215381717596 NeoPharm, Inc. Announces Second Quarter 2008 Financial Results- August 14, 2008 (Yahoo) For the second quarter ended June 30, 2008, NeoPharm reported a net loss of $2.1 million, or ($0.07) per basic and diluted share, as compared to a net loss of $3.6 million, or ($0.13) per share, for the same period last year, which represents a $1.5 million, or 42%, reduction. For the six months ended June 30, 2008, NeoPharm reported a net loss of $3.6 million, or ($0.13) per basic and diluted share, compared to a net loss of $9.1 million, or ($0.32) per share, for the same period last..http://biz.yahoo.com/bw/080814/20080814006027.html?.v=1 Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Second Quarter and Year-to-Date 2008 Financial Results- August 14, 2008 (Yahoo) SAN DIEGO, Aug. 14 PRNewswire-FirstCall -- Ardea Biosciences, Inc. (Nasdaq: RDEA - News), a company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), gout, cancer and inflammatory diseases today reported recent accomplishments and financial results for the three and six months ended June 30, 2008.http://biz.yahoo.com/prnews/080814/aqth526.html?.v=15 CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)- August 14, 2008 (Yahoo) PALO ALTO, Calif., Aug. 14 PRNewswire-FirstCall -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(ranolazine).http://biz.yahoo.com/prnews/080814/nyth097.html?.v=101 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab- August 14, 2008 (Yahoo) BETHESDA, Md., Aug. 14 PRNewswire-FirstCall -- Micromet, Inc. (Nasdaq: MITI - News), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced publication of a Phase 1 clinical study(1) on its BiTEantibody blinatumomab (MT103MEDI-538) in this week's issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune.http://biz.yahoo.com/prnews/080814/nyth065.html?.v=101 amfAR Announces Appointment of Bradley Jensen as New CFO- August 14, 2008 (VPO) NEW YORK --(Business Wire)-- Aug. 14, 2008 amfAR, The Foundation for AIDS Research, has appointed Bradley Jensen as its new chief financial officer, amfAR CEO Kevin Robert Frost announced today. Jensen comes to amfAR from the Global Alliance for TB Drug Development (TB Alliance) and brings with him a wealth of experience in the global financial arena.http://www.virtualpressoffice.com/press/index.jsp?pressId=1215381715632 |